{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:08:32Z","timestamp":1791054512432,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.molmed.2010.10.005","type":"journal-article","created":{"date-parts":[[2010,11,24]],"date-time":"2010-11-24T09:51:36Z","timestamp":1290592296000},"page":"34-46","source":"Crossref","is-referenced-by-count":30,"title":["Mixing the right hepatitis C inhibitor cocktail"],"prefix":"10.1016","volume":"17","author":[{"given":"Michael A.","family":"Gelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2010.10.005_bib0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int."},{"key":"10.1016\/j.molmed.2010.10.005_bib0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/0091270003258669","article-title":"Global burden of disease (GBD) for hepatitis C","volume":"44","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/jlts.2003.50268","article-title":"Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on Liver Transplantation and Hepatitis C","volume":"9","author":"Wiesner","year":"2003","journal-title":"Liver Transpl."},{"key":"10.1016\/j.molmed.2010.10.005_bib0020","series-title":"Chronic Viral Hepatitis: Diagnosis and Therapeutics","first-page":"431","article-title":"Viral hepatitis and hepatocellular carcinoma","author":"Marrero","year":"2009"},{"key":"10.1016\/j.molmed.2010.10.005_bib0025","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1073\/pnas.87.6.2057","article-title":"Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups","volume":"87","author":"Miller","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2010.10.005_bib0030","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1128\/JVI.00753-07","article-title":"Studying hepatitis C virus: making the best of a bad virus","volume":"81","author":"Tellinghuisen","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrgastro.2009.32","article-title":"Mechanisms of HCV survival in the host","volume":"6","author":"Sklan","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0040","first-page":"17","article-title":"Hepatitis C virus: molecular biology & current therapeutic options","volume":"131","author":"Sharma","year":"2010","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.molmed.2010.10.005_bib0045","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1172\/JCI39133","article-title":"Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence","volume":"119","author":"Rehermann","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2010.10.005_bib0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1665-2681(19)31786-7","article-title":"Current and future treatment options for HCV","volume":"8","author":"Kronenberger","year":"2009","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0055","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2010.10.005_bib0060","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2010.10.005_bib0065","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1053\/j.gastro.2010.02.009","article-title":"Replicated association between an IL28B gene variant and a sustained response to Pegylated interferon and ribavirin","volume":"138","author":"McCarthy","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0070","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/j.1572-0241.2005.41860.x","article-title":"Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection","volume":"100","author":"Bini","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1017\/S0266462309090229","article-title":"Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice","volume":"25","author":"Grishchenko","year":"2009","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.molmed.2010.10.005_bib0080","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/nbt.1490","article-title":"Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis","volume":"26","author":"Einav","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0085","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cld.2009.05.004","article-title":"Novel interferons for treatment of hepatitis C virus","volume":"13","author":"Clark","year":"2009","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.molmed.2010.10.005_bib0090","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11894-009-0085-4","article-title":"Treatment of hepatitis C in 2011: what can we expect? Curr","volume":"12","author":"Shiffman","year":"2010","journal-title":"Gastroenterol. Rep."},{"key":"10.1016\/j.molmed.2010.10.005_bib0095","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.molmed.2010.04.003","article-title":"Virus\u2013host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies","volume":"16","author":"Georgel","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2010.10.005_bib0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2010.10.005_bib0105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.molmed.2010.10.005_bib0110","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.molmed.2010.10.005_bib0115","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","article-title":"Efficient initiation of HCV RNA replication in cell culture","volume":"290","author":"Blight","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.molmed.2010.10.005_bib0120","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2010.10.005_bib0125","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vitro","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2010.10.005_bib0130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.antiviral.2008.07.006","article-title":"The human liver\u2013uPA\u2013SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV","volume":"80","author":"Meuleman","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.molmed.2010.10.005_bib0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1054-3589(07)56009-6","article-title":"Viral drug resistance and fitness","volume":"56","author":"Qui\u00f1onesMateu","year":"2008","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0140","series-title":"MacSynergy II Manual","author":"Prichard","year":"1993"},{"key":"10.1016\/j.molmed.2010.10.005_bib0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/653080","article-title":"The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors","volume":"202","author":"Einav","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molmed.2010.10.005_bib0150","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jac\/dkl386","article-title":"Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation","volume":"58","author":"Braithwaite","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.molmed.2010.10.005_bib0155","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/157488710792007293","article-title":"Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials","volume":"5","author":"Chary","year":"2010","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.molmed.2010.10.005_bib0160","first-page":"821","article-title":"A review of HCV protease inhibitors","volume":"10","author":"Chen","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.molmed.2010.10.005_bib0165","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cld.2009.05.009","article-title":"Telaprevir: hope on the horizon, getting closer","volume":"13","author":"Weisberg","year":"2009","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.molmed.2010.10.005_bib0170","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12325-010-0047-0","article-title":"Telaprevir: a new hope in the treatment of chronic hepatitis C?","volume":"27","author":"Fowell","year":"2010","journal-title":"Adv. Ther."},{"key":"10.1016\/j.molmed.2010.10.005_bib0175","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cld.2009.05.008","article-title":"Boceprevir, an NS3 protease inhibitor of HCV","volume":"13","author":"Berman","year":"2009","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.molmed.2010.10.005_bib0180","first-page":"181","article-title":"Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection","volume":"10","author":"Mederacke","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.molmed.2010.10.005_bib0185","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/S0168-8278(10)60763-5","article-title":"Identification and preclinical profile of the novel HCV NS3 protease inhibitor BMS-650032","volume":"52","author":"McPhee","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0190","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0168-8278(10)60751-9","article-title":"Early on-treatment responses during pegylated IFN plus ribavirin are increased following 13 days of combination nucleoside polymerase (RG7128) and protease (RG7227) inhibitor therapy (INFORM-1)","volume":"52","author":"Gane","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0195","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cld.2009.05.001","article-title":"HCV NS5B polymerase inhibitors","volume":"13","author":"Burton","year":"2009","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.molmed.2010.10.005_bib0200","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11904-010-0051-7","article-title":"New frontiers of HCV therapy in HIV\/HCV co-infection","volume":"7","author":"Amorosa","year":"2010","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.molmed.2010.10.005_bib0205","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/S0168-8278(09)60942-9","article-title":"Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor VCH-222 following single dose administration in healthy volunteers and antiviral activity in HCV-infected individuals","volume":"50","author":"Cooper","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0210","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1155\/2007\/231636","article-title":"Complementary and alternative medicine use by patients chronically infected with hepatitis C virus","volume":"21","author":"White","year":"2007","journal-title":"Can. J. Gastroenterol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0215","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1053\/j.gastro.2009.11.053","article-title":"Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase","volume":"138","author":"Ahmed-Belkacem","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0220","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/hep.23587","article-title":"Multiple effects of silymarin on the hepatitis C virus lifecycle","volume":"51","author":"Wagoner","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0525","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1053\/j.gastro.2008.07.072","article-title":"Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon\/ribavirin therapy","volume":"135","author":"Ferenci","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0225","unstructured":"Payer, B.A. et al. (2010) Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J. Clin. Virol. 49, 131\u2013133"},{"key":"10.1016\/j.molmed.2010.10.005_bib0230","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1128\/JVI.76.12.5974-5984.2002","article-title":"Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex","volume":"76","author":"Egger","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2010.03.013","article-title":"A small molecule inhibits HCV replication and alters NS4B's subcellular distribution","volume":"87","author":"Bryson","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.molmed.2010.10.005_bib0240","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1128\/JVI.00875-08","article-title":"A genetic interaction between hepatitis C virus NS4B and NS3 is important for RNA replication","volume":"82","author":"Paredes","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000331","article-title":"Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B","volume":"2","author":"Cho","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2010.10.005_bib0250","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2010.10.005_bib0255","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1016\/S0168-8278(10)61190-7","article-title":"Once-daily NS5A inhibitor (BMS-790052) plus PEGinterferon-alpha-2a and ribavirin produces high rates of extended rapid virologic response in treatment-naive HCV-genotype 1 subjects: Phase 2a trial","volume":"52","author":"Pol","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0260","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0168-8278(10)60035-9","article-title":"Identification and characterization of PPI-461, a potent and selective HCV NS5A inhibitor with activity against all HCV genotypes","volume":"52","author":"Colonno","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0265","first-page":"175","article-title":"Inhibition of HCV p7 as a therapeutic target","volume":"11","author":"Griffin","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.molmed.2010.10.005_bib0270","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/hep.22555","article-title":"Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel","volume":"48","author":"Griffin","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0275","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2004.05.019","article-title":"Evaluation of amantadine in chronic hepatitis C: a meta-analysis","volume":"41","author":"Deltenre","year":"2004","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0280","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cld.2009.05.002","article-title":"Cyclophilin inhibitors","volume":"13","author":"Gallay","year":"2009","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.molmed.2010.10.005_bib0285","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jhep.2010.01.041","article-title":"HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors","volume":"53","author":"Chatterji","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0290","first-page":"213","article-title":"Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection","volume":"11","author":"Watashi","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.molmed.2010.10.005_bib0295","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0168-8278(09)60090-8","article-title":"Particular in vitro anti-HCV activities and resistance profile of the cyclophilin inhibitor Debio 025","volume":"50","author":"Coelmont","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0300","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22835","article-title":"The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients","volume":"49","author":"Flisiak","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0305","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0168-8278(09)60097-0","article-title":"Efficacy and safety of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon Alpha-2a and ribavirin in previously null-responder genotype 1 HCV patients","volume":"50","author":"Nelson","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0310","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/S0168-8278(09)60624-3","article-title":"Safety and tolerability of Nim811, a novel cyclophilin inhibitor for HCV, following single and multiple ascending doses in healthy volunteers and HCV-infected patients","volume":"50","author":"Ke","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0315","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/S0168-8278(09)61047-3","article-title":"Safety and antiviral efficacy of 14 days of the cyclophilin inhibitor Nim811 in combination with pegylated interferon alpha2a in relapsed genotype 1 HCV infected patients","volume":"50","author":"Lawitz","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0320","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/AAC.00660-09","article-title":"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro","volume":"54","author":"Hopkins","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.molmed.2010.10.005_bib0325","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0168-8278(09)60091-X","article-title":"Safety, plasma pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection","volume":"50","author":"Hopkins","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0330","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0168-8278(10)60036-0","article-title":"Resistance selection following 15 days of monotherapy with SCY-635, a non-immunosuppressive cyclophilin inhibitor with potent anti-HCV activity","volume":"52","author":"Hopkins","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0335","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3748\/wjg.15.1805","article-title":"Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides","volume":"15","author":"Keeffe","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0340","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2009.07.056","article-title":"The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation","volume":"137","author":"Elazar","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0345","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2007.08.005","article-title":"Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication","volume":"77","author":"Korba","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.molmed.2010.10.005_bib0350","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2036.2008.03781.x","article-title":"Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4","volume":"28","author":"Rossignol","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2010.10.005_bib0355","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2008.11.037","article-title":"Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, PEGinterferon, and ribavirin","volume":"136","author":"Rossignol","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0360","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(08)60070-7","article-title":"Randomized controlled trial of nitazoxanide\u2013PEGinterferon\u2013ribavirin, Nitazoxanide\u2013PEGinterferon and PEGinterferon\u2013ribavirin in the treatment of patients with chronic hepatitis C genotype 4","volume":"48","author":"Rossignol","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0365","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.1016\/S0168-8278(08)60834-X","article-title":"Evaluation of a 4 week lead-in phase with nitazoxanide prior to nitazoxanide+PEGinterferon in treating chronic hepatitis C","volume":"48","author":"Rossignol","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0370","doi-asserted-by":"crossref","first-page":"S461","DOI":"10.1016\/S0168-8278(10)61189-0","article-title":"Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with PEGinterferon alpha-2a and ribavirin in nonresponders (NR) with chronic hepatitis C genotype 1: final report","volume":"52","author":"Shiffman","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0375","doi-asserted-by":"crossref","first-page":"S463","DOI":"10.1016\/S0168-8278(10)61192-0","article-title":"Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus PEGinterferon and ribavirin in HCV genotype 1 naive patients: week 12 sustained virologic response rate","volume":"52","author":"Bacon","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0380","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/gut.2008.156307","article-title":"Toll-like receptors as targets in chronic liver diseases","volume":"58","author":"Mencin","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.molmed.2010.10.005_bib0385","first-page":"702","article-title":"Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease","volume":"7","author":"Fletcher","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.molmed.2010.10.005_bib0390","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1073\/pnas.1002301107","article-title":"Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection","volume":"107","author":"Takahashi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2010.10.005_bib0395","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hep.20839","article-title":"Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection","volume":"42","author":"Horsmans","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0400","first-page":"1022A","article-title":"ANA773, an oral inducer of endogenous interferons that acts via TLR7, reduced serum viral load in patients chronically infected with HCV","volume":"50","author":"Janssen","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0405","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0168-8278(10)60034-7","article-title":"A phase 1, multi-center, randomized, placebo-controlled, dose-escalation study of IMO-2125, a TLR9 agonist, in hepatitis C-nonresponders","volume":"52","author":"Muir","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0410","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12026-009-8152-3","article-title":"Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence","volume":"47","author":"Burke","year":"2010","journal-title":"Immunol. Res."},{"key":"10.1016\/j.molmed.2010.10.005_bib0415","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2007.12.014","article-title":"Restoration of HCV-specific T cell functions by PD-1\/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment","volume":"48","author":"Urbani","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0420","doi-asserted-by":"crossref","first-page":"e1000313","DOI":"10.1371\/journal.ppat.1000313","article-title":"Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1\/CTLA-4 blockade","volume":"5","author":"Nakamoto","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molmed.2010.10.005_bib0425","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0168-8278(09)60122-7","article-title":"Functional T cell restoration induced by PD-1\/PD-L1 blockade in chronic hepatitis B and C is improved by simultaneous modulation of the co-stimulatory CD137\/CD137L pathway","volume":"50","author":"Fisicaro","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0430","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1073\/pnas.0712380105","article-title":"A virocidal amphipathic alpha-helical peptide that inhibits hepatitis C virus infection in vitro","volume":"105","author":"Cheng","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2010.10.005_bib0435","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1021\/cb900149b","article-title":"Mechanism of an amphipathic alpha-helical peptide's antiviral activity involves size-dependent virus particle lysis","volume":"4","author":"Cho","year":"2009","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0440","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1086\/525287","article-title":"Targeting lipid metabolism in the treatment of hepatitis C virus infection","volume":"197","author":"Amemiya","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molmed.2010.10.005_bib0445","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cell.2010.03.050","article-title":"Viral reorganization of the secretory pathway generates distinct organelles for RNA replication","volume":"141","author":"Hsu","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2010.10.005_bib0450","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1254\/jphs.FM0070050","article-title":"Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon","volume":"105","author":"Ikeda","year":"2007","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.molmed.2010.10.005_bib0455","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1073\/pnas.0409834102","article-title":"Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids","volume":"102","author":"Kapadia","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2010.10.005_bib0460","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1073\/pnas.0902693106","article-title":"Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication","volume":"106","author":"Berger","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2010.10.005_bib0465","doi-asserted-by":"crossref","first-page":"10058","DOI":"10.1128\/JVI.02418-08","article-title":"Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication","volume":"83","author":"Borawski","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0470","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.chom.2009.02.001","article-title":"A functional genomic screen identifies cellular cofactors of hepatitis C virus replication","volume":"5","author":"Tai","year":"2009","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.molmed.2010.10.005_bib0475","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1096\/fj.09-131920","article-title":"Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening","volume":"23","author":"Trotard","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.molmed.2010.10.005_bib0480","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.virol.2009.02.039","article-title":"Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication","volume":"387","author":"Vaillancourt","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0485","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1016\/S0168-8278(09)60949-1","article-title":"A newly synthesized serine palmitoyltransferase inhibitor, NA 808, has the strong effect to hepatitis C virus in vitro and in vivo","volume":"50","author":"Hirata","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0490","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1042\/BC20090125","article-title":"Role of lipid metabolism in hepatitis C virus assembly and entry","volume":"102","author":"Popescu","year":"2010","journal-title":"Biol. Cell"},{"key":"10.1016\/j.molmed.2010.10.005_bib0495","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.4161\/cc.8.10.8349","article-title":"Activation of hepatitis C virus translation by a liver-specific microRNA","volume":"8","author":"Niepmann","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.molmed.2010.10.005_bib0500","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1178178","article-title":"Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection","volume":"327","author":"Lanford","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.molmed.2010.10.005_bib0505","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2008.02.058","article-title":"Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41","volume":"134","author":"Klade","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2010.10.005_bib0510","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1016\/j.vaccine.2009.06.027","article-title":"Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C","volume":"27","author":"Wedemeyer","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.molmed.2010.10.005_bib0515","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jhep.2010.05.007","article-title":"A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals","volume":"53","author":"Gowans","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2010.10.005_bib0520","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/gut.2005.074062","article-title":"Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C","volume":"55","author":"Diago","year":"2006","journal-title":"Gut"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491410001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491410001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T02:03:07Z","timestamp":1592100187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491410001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1471491410001516"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2010.10.005","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}